CRISM Therapeutics trades just above 10p placing level ahead of key ChemoSeed trial update

LONDON, July 5, 2026, 16:02 BST

• CRISM closed Friday at 10.50p, up 10.53%. Volume topped 1 million shares.
• The shares closed roughly 5% higher than the 10p price from the May/June equity raise and the director option awards this week.
• Spreadex lowered its total disclosed stake to 2.9050% from 3.4733%. The cut came from CFDs and spread bets.
• The next operating update is a site initiation visit set for late July ahead of patient recruitment.

CRISM Therapeutics Corporation LON:CRTX closed out last week trading a touch over 10p, the same price as its most recent fundraising. Investors looked at a modest move up in the AIM-listed shares as new details came out on ownership and options ahead of a clinical trial site update expected later this month.

London markets didn’t open Sunday. AJ Bell last quoted CRISM at 10.50p, up 1.00p or 10.53%, with volume at 1,043,387 shares. The broker’s site listed a 10.00p sell price and 11.00p buy price. Shares opened at 9.50p and hit a 10.48p session high. Market cap stood at £8.31 million. On July 3, the same feed had the FTSE AIM All Share off 0.17%.

The 10p mark is key for CRISM after the company tied both its June funding and this week’s management awards to that price. In its annual results, CRISM said it closed a “significantly oversubscribed” £2.745 million fundraise in May and June at 10p a share. The company also reported a £896,088 Innovate UK Biomedical Catalyst grant to cover 70% of Part 1 costs in its Phase 2 trial. Another £99,902 grant from Invest Northern Ireland will back its docetaxel-ChemoSeed prostate cancer project until March 2027. Investegate

CRISM granted options over 1,012,797 shares to Andrew Webb, Chris McConville and Gerry Beaney on June 30. The options carry a 10p exercise price and vest in thirds through June 2028, with expiration set for June 2036. If fully exercised, those options would equal about 1.28% of current voting rights, based on the July 2 notice.

Spreadex LTD cut its total stake to 2.9050% from 3.4733%, the ownership filing showed. The firm’s direct voting rights holding stayed at 2 million shares, or 2.5257%. Its CFD and spread bet position dropped to 300,374 voting rights, or 0.3793%, compared to 0.9476% earlier. That trims derivative-linked exposure by about 450,000 voting rights.

The stock has about 79.2 million implied voting rights, so it’s not big by market standards, but that stands out when Friday’s turnover was just 1.04 million shares. This happened the same week as the option grant, so both the shareholder register and the 10p price matter more than just the daily move.

CRISM set out a short-term timeline, telling investors it finished its manufacturing, quality, regulatory, and startup tasks. Site activation is almost done, and a site visit is set for late July. The company said it still expects to dose the first patient “as soon as practicable.” Investegate

Executive Chairman Andrew Webb said in the annual-results release that CRISM is “well funded,” and that glioblastoma treatment options have “barely changed in over 20 years.” The ChemoSeed implant aims to get chemotherapy straight into the tumour or into tissue left after tumour removal. Investegate

CRISM’s cash base is still slim. The company reported £1.128 million in cash at year end, down from £1.282 million the year before. Losses grew to £1.903 million, compared to £607,000, as admin and R&D spending picked up ahead of the Phase 2 study. Net cash used in operations hit £1.967 million, up from £933,000 last year.

This week, focus shifts from AIM biotech sentiment to CRISM and whether it can hold its late-July site marker. The company has raised new equity, picked up grant support and reset management options at around 10p.